The Cell Biology of Acute Childhood Respiratory Disease: Therapeutic Implications

Pediatric Clinics of North America

Volumn 53, Issue 5, 2006, Pages 929-959

  Loughlin, Gerald M ^a   Moscona, Anne ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIVIRUS AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DORNASE ALFA; ENFUVIRTIDE; HYBRID PROTEIN; LIVE VACCINE; MEDI 524; MONTELUKAST; PALIVIZUMAB; PARAINFLUENZA VACCINE; PURIFIED FUSION PROTEIN 1; PURIFIED FUSION PROTEIN 2; PURIFIED FUSION PROTEIN 3; RECOMBINANT VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; RIBAVIRIN; SURFACTANT; THEOPHYLLINE; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS VACCINE;

ACTIVE IMMUNIZATION; ASTHMA; BRONCHIOLITIS; CLINICAL TRIAL; CYSTIC FIBROSIS; CYTOLOGY; DISEASE SEVERITY; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; IMMUNOPATHOGENESIS; IMMUNOPROPHYLAXIS; MORBIDITY; MORTALITY; NONHUMAN; PARAINFLUENZA VIRUS; PASSIVE IMMUNIZATION; PATHOGENESIS; PEDIATRICS; PNEUMONIA; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFECTION; REVIEW; VIRUS INFECTION;

ACUTE DISEASE; CHILD, PRESCHOOL; HUMANS; IMMUNIZATION; INFANT; INFANT, NEWBORN; RESPIRATORY TRACT INFECTIONS;

EID: 33749244669     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcl.2006.08.004     Document Type: Review

References (167)

1. Williams J.V., Harris P.A., Tollefson S.J., et al. Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children. N Engl J Med 350 5 (2004) 443-450
2. Collins P., Chanock R., and McIntosh K. Parainfluenza viruses. In: Fields B., Knipe D.M., and Howley P. (Eds). Fields virology (1996), Lippincott-Raven Publishers, Philadelphia 1205-1241
3. Poehling K.A., Edwards K.M., Weinberg G.A., et al. The underrecognized burden of influenza in young children. N Engl J Med 355 1 (2006) 31-40
4. Michaud C.M., Murray C.J., and Bloom B.R. Burden of disease-implications for future research. JAMA 285 5 (2001) 535-539
5. Choi E.H., Lee H.J., Yoo T., and Chanock S.J. A common haplotype of interleukin-4 gene IL4 is associated with severe respiratory syncytial virus disease in Korean children. J Infect Dis 186 9 (2002) 1207-1211
6. Hoebee B., Rietveld E., Bont L., et al. Association of severe respiratory syncytial virus bronchiolitis with interleukin-4 and interleukin-4 receptor alpha polymorphisms. J Infect Dis 187 1 (2003) 2-11
7. Hoebee B., Bont L., Rietveld E., van, et al. Influence of promoter variants of interleukin-10, interleukin-9, and tumor necrosis factor-alpha genes on respiratory syncytial virus bronchiolitis. J Infect Dis 189 2 (2004) 239-247
8. Wilson J., Rowlands K., Rockett K., et al. Genetic variation at the IL10 gene locus is associated with severity of respiratory syncytial virus bronchiolitis. J Infect Dis 191 10 (2005) 1705-1709
9. Hull J., Ackerman H., Isles K., et al. Unusual haplotypic structure of IL8, a susceptibility locus for a common respiratory virus. Am J Hum Genet 69 2 (2001) 413-419
10. Hull J., Rowlands K., Lockhart E., et al. Haplotype mapping of the bronchiolitis susceptibility locus near IL8. Hum Genet 114 3 (2004) 272-279
11. Hull J., Rowlands K., Lockhart E., et al. Variants of the chemokine receptor CCR5 are associated with severe bronchiolitis caused by respiratory syncytial virus. J Infect Dis 188 6 (2003) 904-907
12. Lahti M., Lofgren J., Marttila R., et al. Surfactant protein D gene polymorphism associated with severe respiratory syncytial virus infection. Pediatr Res 51 6 (2002) 696-699
13. Lofgren J., Ramet M., Renko M., et al. Association between surfactant protein A gene locus and severe respiratory syncytial virus infection in infants. J Infect Dis 185 3 (2002) 283-289
14. Ehlenfield D.R., Cameron K., and Welliver R.C. Eosinophilia at the time of respiratory syncytial virus bronchiolitis predicts childhood reactive airway disease. Pediatrics 105 1 Pt 1 (2000) 79-83
15. Anderson L.J., and Heilman C.A. Protective and disease-enhancing immune responses to respiratory syncytial virus. J Infect Dis 171 1 (1995) 1-7
16. Falsey A.R., and Walsh E.E. Relationship of serum antibody to risk of respiratory syncytial virus infection in elderly adults. J Infect Dis 177 2 (1998) 463-466
17. Welliver R.C. Immunology of respiratory syncytial virus infection: eosinophils, cytokines, chemokines and asthma. Pediatr Infect Dis J 19 8 (2000) 780-783 [discussion: 784-5; 811-3]
18. van Schaik S.M., Obot N., Enhorning G., et al. Role of interferon gamma in the pathogenesis of primary respiratory syncytial virus infection in BALB/c mice. J Med Virol 62 2 (2000) 257-266
19. van Schaik S.M., Welliver R.C., and Kimpen J.L. Novel pathways in the pathogenesis of respiratory syncytial virus disease. Pediatr Pulmonol 30 2 (2000) 131-138
20. Srikiatkhachorn A., and Braciale T.J. Virus-specific memory and effector T lymphocytes exhibit different cytokine responses to antigens during experimental murine respiratory syncytial virus infection. J Virol 71 1 (1997) 678-685
21. Alwan W.H., Kozlowska W.J., and Openshaw P.J. Distinct types of lung disease caused by functional subsets of antiviral T cells. J Exp Med 179 1 (1994) 81-89
22. Openshaw P.J., Clarke S.L., and Record F.M. Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G. Int Immunol 4 4 (1992) 493-500
23. Cannon M.J., Openshaw P.J., and Askonas B.A. Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus. J Exp Med 168 3 (1988) 1163-1168
24. Haeberle H.A., Takizawa R., Casola A., et al. Respiratory syncytial virus-induced activation of nuclear factor-kappaB in the lung involves alveolar macrophages and toll-like receptor 4-dependent pathways. J Infect Dis 186 9 (2002) 1199-1206
25. Haynes L.M., Moore D.D., Kurt-Jones E.A., et al. Involvement of toll-like receptor 4 in innate immunity to respiratory syncytial virus. J Virol 75 22 (2001) 10730-10737
26. Kurt-Jones E.A., Popova L., et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 1 5 (2000) 398-401
27. Scott R., Kaul A., Scott M., et al. Development of in vitro correlates of cell-mediated immunity to respiratory syncytial virus infection in humans. J Infect Dis 137 6 (1978) 810-817
28. Welliver R.C., Kaul T.N., Sun M., et al. Defective regulation of immune responses in respiratory syncytial virus infection. J Immunol 133 4 (1984) 1925-1930
29. Openshaw P.J., Culley F.J., and Olszewska W. Immunopathogenesis of vaccine-enhanced RSV disease. Vaccine 20 Suppl 1 (2001) S27-S31
30. Bont L., Heijnen C.J., Kavelaars A., et al. Local interferon-gamma levels during respiratory syncytial virus lower respiratory tract infection are associated with disease severity. J Infect Dis 184 3 (2001) 355-358
31. Garofalo R.P., Patti J., Hintz K.A., et al. Macrophage inflammatory protein-1alpha (not T helper type 2 cytokines) is associated with severe forms of respiratory syncytial virus bronchiolitis. J Infect Dis 184 4 (2001) 393-399
32. Kim H.W., Canchola J.G., Brandt C.D., et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 89 4 (1969) 422-434
33. Graham B.S. Pathogenesis of respiratory syncytial virus vaccine-augmented pathology. Am J Respir Crit Care Med 152 4 Pt 2 (1995) S63-S66
34. Connors M., Kulkarni A.B., Firestone C.Y., et al. Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+ T cells. J Virol 66 12 (1992) 7444-7451
35. Waris M.E., Tsou C., Erdman D.D., et al. Respiratory syncytial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J Virol 70 5 (1996) 2852-2860
36. Waris M.E., Tsou C., Erdman D.D., et al. Priming with live respiratory syncytial virus (RSV) prevents the enhanced pulmonary inflammatory response seen after RSV challenge in BALB/c mice immunized with formalin-inactivated RSV. J Virol 71 9 (1997) 6935-6939
37. Polack F.P., Teng M.N., Collins P.L., et al. A role for immune complexes in enhanced respiratory syncytial virus disease. J Exp Med 196 6 (2002) 859-865
38. Polack F.P., and Karron R.A. The future of respiratory syncytial virus vaccine development. Pediatr Infect Dis J 23 1 Suppl (2004) S65-S73
39. Englund J. In search of a vaccine for respiratory syncytial virus: the saga continues. J Infect Dis 191 7 (2005) 1036-1039
40. Karron R.A., Wright P.F., Belshe R.B., et al. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis 191 7 (2005) 1093-1104
41. Collins P., Mink M., and Stec D. Rescue of synthetic analogs of respiratory syncytial virus genomic RNA and effect of truncations and mutations on the expression of a foreign reporter gene. Proc Natl Acad Sci U S A 88 (1991) 9663-9667
42. Collins P.L., Hill M.G., Camargo E., et al. Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5′ proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. Proc Natl Acad Sci U S A 92 25 (1995) 11563-11567
43. Murphy B.R., and Collins P.L. Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics. J Clin Invest 110 1 (2002) 21-27
44. Simoes E.A., Tan D.H., Ohlsson A., et al. Respiratory syncytial virus vaccine: a systematic overview with emphasis on respiratory syncytial virus subunit vaccines. Vaccine 20 5-6 (2001) 954-960
45. Munoz F.M., Piedra P.A., and Glezen W.P. Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. Vaccine 21 24 (2003) 3465-3467
46. Plotnicky-Gilquin H., Robert A., Chevalet L., et al. CD4(+) T-cell-mediated antiviral protection of the upper respiratory tract in BALB/c mice following parenteral immunization with a recombinant respiratory syncytial virus G protein fragment. J Virol 74 8 (2000) 3455-3463
47. Power U.F., Nguyen T.N., Rietveld E., et al. Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults. J Infect Dis 184 11 (2001) 1456-1460
48. Ison M.G., Johnston S.L., Openshaw P., et al. Current research on respiratory viral infections: Fifth International Symposium. Antiviral Res 62 3 (2004) 75-110
49. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn. Pediatrics 102 5 (1998) 1211-1216
50. Meissner H.C., and Long S.S. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 112 6 Pt 1 (2003) 1447-1452
51. Wu H., Pfarr D.S., Tang Y., et al. Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization. J Mol Biol 350 1 (2005) 126-144
52. Mejias A., Chavez-Bueno S., Rios A.M., et al. Asthma and respiratory syncytial virus. New opportunities for therapeutic intervention. An Pediatr (Barc) 61 3 (2004) 252-260 [in Spanish]
53. Lamb R. Paramyxovirus fusion: a hypothesis for changes. Virology 197 (1993) 1-11
54. Plemper R.K., Lakdawala A.S., Gernert K.M., et al. Structural features of paramyxovirus F protein required for fusion initiation. Biochemistry 42 22 (2003) 6645-6655
55. Hernandez L.D., Hoffman L.R., Wolfsberg T.G., et al. Virus-cell and cell-cell fusion. Annu Rev Cell Dev Biol 12 (1996) 627-661
56. Colman P.M., and Lawrence M.C. The structural biology of type I viral membrane fusion. Nat Rev Mol Cell Biol 4 4 (2003) 309-319
57. Porotto M., Murrell M., Greengard O., et al. Triggering of human parainfluenza virus 3 fusion protein(F) by the hemagglutinin-neuraminidase (HN): an HN mutation diminishing the rate of F activation and fusion. J Virol 77 6 (2003) 3647-3654
58. Moscona A. Entry of parainfluenza virus into cells as a target for interrupting childhood respiratory disease. J Clin Invest 115 7 (2005) 1688-1698
59. Moscona A., and Peluso R.W. Fusion properties of cells persistently infected with human parainfluenza virus type 3: Participation of hemagglutinin-neuraminidase in membrane fusion. J Virol 65 (1991) 2773-2777
60. Moscona A., and Peluso R.W. Relative affinity of the human parainfluenza virus 3 hemagglutinin-neuraminidase for sialic acid correlates with virus-induced fusion activity. J Virol 67 (1993) 6463-6468
61. Porotto M., Murrell M., Greengard O., et al. Influence of the human parainfluenza virus 3 attachment protein's neuraminidase activity on its capacity to activate the fusion protein. J Virol 79 4 (2005) 2383-2392
62. Russell C.J., Jardetzky T.S., and Lamb R.A. Membrane fusion machines of paramyxoviruses: capture of intermediates of fusion. EMBO J 20 15 (2001) 4024-4034
63. Wild C.T., Shugars D.C., Greenwell T.K., et al. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci U S A 91 21 (1994) 9770-9774
64. Wild C., Oas T., McDanal C., et al. A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc Natl Acad Sci U S A 89 21 (1992) 10537-10541
65. Eckert D.M., and Kim P.S. Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region. Proc Natl Acad Sci U S A 98 20 (2001) 11187-11192
66. Rapaport D., Ovadia M., and Shai Y. A synthetic peptide corresponding to a conserved heptad repeat domain is a potent inhibitor of Sendai virus-cell fusion: an emerging similarity with functional domains of other viruses. EMBO J 14 22 (1995) 5524-5531
67. Lambert D.M., Barney S., Lambert A.L., et al. Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. Proc Natl Acad Sci U S A 93 5 (1996) 2186-2191
68. Yao Q., and Compans R.W. Peptides corresponding to the heptad repeat sequence of human parainfluenza virus fusion protein are potent inhibitors of virus infection. Virology 223 1 (1996) 103-112
69. Baker K.A., Dutch R.E., Lamb R.A., et al. Structural basis for paramyxovirus-mediated membrane fusion. Mol Cell 3 3 (1999) 309-319
70. Lu M., Blacklow S.C., and Kim P.S. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol 2 12 (1995) 1075-1082
71. Porotto M., Doctor L., Carta P., et al. Inhibition of Hendra virus membrane fusion. J Virol (2006) In press
72. Joshi S.B., Dutch R.E., and Lamb R.A. A core trimer of the paramyxovirus fusion protein: parallels to influenza virus hemagglutinin and HIV-1 gp41. Virology 248 1 (1998) 20-34
73. Wild T.F., and Buckland R. Inhibition of measles virus infection and fusion with peptides corresponding to the leucine zipper region of the fusion protein. J Gen Virol 78 Pt 1 (1997) 107-111
74. Young J.K., Hicks R.P., Wright G.E., et al. Analysis of a peptide inhibitor of paramyxovirus (NDV) fusion using biological assays, NMR, and molecular modeling. Virology 238 2 (1997) 291-304
75. Young J.K., Li D., Abramowitz M.C., et al. Interaction of peptides with sequences from the newcastle disease virus fusion protein heptad repeat regions. J Virol 73 7 (1999) 5945-5956
76. Chan D.C., Chutkowski C.T., and Kim P.S. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc Natl Acad Sci U S A 95 26 (1998) 15613-15617
77. Cianci C., Langley D.R., Dischino D.D., et al. Targeting a binding pocket within the trimer-of-hairpins: small-molecule inhibition of viral fusion. Proc Natl Acad Sci U S A 101 42 (2004) 15046-15051
78. Maggon K., and Barik S. New drugs and treatment for respiratory syncytial virus. Rev Med Virol 14 3 (2004) 149-168
79. Chanock R.M. Control of pediatric viral diseases: past successes and future prospects. Pediatr Res 27 6 Suppl (1990) S39-S43
80. Murphy B.R. Current approaches to the development of vaccines effective against parainfluenza viruses. Bull World Health Organ 66 3 (1988) 391-397
81. Groothuis J., Simoes E., Levin M., et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med 329 (1993) 1524-1530
82. Aherne W., Bird T., Court S., et al. Pathological changes in virus infections of the lower respiratory tract in children. J Clin Pathol 23 (1970) 7-18
83. Downham M., Gardner P., McQuillin J., et al. Role of respiratory viruses in childhood mortality. Br Med J 1 (1975) 235-239
84. Smith C., Purcell R., Bellanti J., et al. Protective effect of antibody to parainfluenza type 1 virus. N Engl J Med 275 (1966) 1145-1152
85. Tremonti L., Lin J., and Jackson G. Neutralizing activity in nasal secretions and serum in resistance of volunteers to parainfluenza virus type 2. J Immunol 101 (1968) 572-577
86. Wendt C., Weisdorf D., Jordan M., et al. Parainfluenza virus respiratory infection after bone marrow transplantation. N Engl J Med 326 (1992) 921-926
87. Porter D., Prince G., Hemming V., et al. Pathogenesis of human parainfluenza virus 3 infection in two species of cotton rat: Sigmodon hispidus develops bronchiolitis, while Sigmodon fulviventer develops interstitial pneumonia. J Virol 65 (1991) 103-111
88. Prince G.A., Ottolini M.G., and Moscona A. Contribution of the human parainfluenza virus type 3 HN-receptor interaction to pathogenesis in vivo. J Virol 75 24 (2001) 12446-12451
89. Chin J., Magoffin R., Shearer L., et al. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol 89 (1969) 449-463
90. Fulginiti V., Eller J., Sieber O., et al. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol 89 (1969) 435-448
91. Belshe R.B., Newman F.K., Tsai T.F., et al. Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old. J Infect Dis 189 3 (2004) 462-470
92. Karron R.A., Belshe R.B., Wright P.F., et al. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants. Pediatr Infect Dis J 22 5 (2003) 394-405
93. Madhi S.A., Cutland C., Zhu Y., et al. Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlers. Vaccine 24 13 (2006) 2432-2439
94. Greenberg D.P., Walker R.E., Lee M.S., et al. A bovine parainfluenza virus type 3 vaccine is safe and immunogenic in early infancy. J Infect Dis 191 7 (2005) 1116-1122
95. Newman J.T., Riggs J.M., Surman S.R., et al. Generation of recombinant human parainfluenza virus type 1 vaccine candidates by importation of temperature-sensitive and attenuating mutations from heterologous paramyxoviruses. J Virol 78 4 (2004) 2017-2028
96. Haller A.A., Miller T., Mitiku M., et al. Expression of the surface glycoproteins of human parainfluenza virus type 3 by bovine parainfluenza virus type 3, a novel attenuated virus vaccine vector. J Virol 74 24 (2000) 11626-11635
97. Pennathur S., Haller A.A., MacPhail M., et al. Evaluation of attenuation, immunogenicity and efficacy of a bovine parainfluenza virus type 3 (PIV-3) vaccine and a recombinant chimeric bovine/human PIV-3 vaccine vector in rhesus monkeys. J Gen Virol 84 Pt 12 (2003) 3253-3261
98. Schmidt A.C., McAuliffe J.M., Huang A., et al. Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates. J Virol 74 19 (2000) 8922-8929
99. Bukreyev A., Lamirande E.W., Buchholz U.J., et al. Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet 363 9427 (2004) 2122-2127
100. Bukreyev A., Yang L., Zaki S.R., et al. A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge. J Virol 80 5 (2006) 2267-2279
101. Belshe R.B., Newman F.K., Anderson E.L., et al. Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children. J Infect Dis 190 12 (2004) 2096-2103
102. Karron R., Wright P., Newman F., et al. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in healthy infants and children. J Infect Dis 172 (1995) 1445-1450
103. Huberman K., Peluso R., and Moscona A. The hemagglutinin-neuraminidase of human parainfluenza virus type 3: role of the neuraminidase in the viral life cycle. Virology 214 (1995) 294-300
104. Murrell M., Porotto M., Weber T., et al. Mutations in human parainfluenza virus type 3 HN causing increased receptor binding activity and resistance to the transition state sialic acid analog 4-GU-DANA (zanamivir). J Virol 77 (2003) 309-317
105. Lawrence M.C., Borg N.A., Streltsov V.A., et al. Structure of the haemagglutinin-neuraminidase from human parainfluenza virus type III. J Mol Biol 335 5 (2004) 1343-1357
106. Porotto M., Murrell M., Greengard O., et al. Inhibition of parainfluenza type 3 and Newcastle disease virus hemagglutinin-neuraminidase receptor binding: effect of receptor avidity and steric hindrance at the inhibitor binding sites. J Virol 78 24 (2004) 13911-13919
107. Porotto M., Fornabaio M., Greengard O., et al. Paramyxovirus receptor-binding molecules: engagement of one site on the hemagglutinin-neuraminidase protein modulates activity at the second site. J Virol 80 3 (2006) 1204-1213
108. Alymova I.V., Portner A., Takimoto T., et al. The novel parainfluenza virus hemagglutinin-neuraminidase inhibitor BCX 2798 prevents lethal synergism between a paramyxovirus and Streptococcus pneumoniae. Antimicrob Agents Chemother 49 1 (2005) 398-405
109. Yin H.S., Wen X., Paterson R.G., et al. Structure of the parainfluenza virus 5 F protein in its metastable, perfusion conformation. Nature 439 7072 (2006) 38-44
110. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med 353 (2005) 1363-1373
111. Porotto M., Greengard O., Poltoratskaia N., et al. Human parainfluenza virus type 3 HN-receptor interaction: the effect of 4-GU-DANA on a neuraminidase-deficient variant. J Virol 76 (2001) 7481-7488
112. van den Hoogen B.G., de Jong J.C., Groen J., et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med 7 6 (2001) 719-724
113. Boivin G., Abed Y., Pelletier G., et al. Virological features and clinical manifestations associated with human metapneumovirus: a new paramyxovirus responsible for acute respiratory-tract infections in all age groups. J Infect Dis 186 9 (2002) 1330-1334
114. Williams J.V., Wang C.K., Yang C.F., et al. The role of human metapneumovirus in upper respiratory tract infections in children: a 20-year experience. J Infect Dis 193 3 (2006) 387-395
115. Jartti T., van den Hoogen B., Garofalo R.P., et al. Metapneumovirus and acute wheezing in children. Lancet 360 9343 (2002) 1393-1394
116. Skiadopoulos M.H., Biacchesi S., Buchholz U.J., et al. The two major human metapneumovirus genetic lineages are highly related antigenically, and the fusion (F) protein is a major contributor to this antigenic relatedness. J Virol 78 13 (2004) 6927-6937
117. MacPhail M., Schickli J.H., Tang R.S., et al. Identification of small-animal and primate models for evaluation of vaccine candidates for human metapneumovirus (hMPV) and implications for hMPV vaccine design. J Gen Virol 85 Pt 6 (2004) 1655-1663
118. Williams J.V., Tollefson S.J., Johnson J.E., et al. The cotton rat (Sigmodon hispidus) is a permissive small animal model of human metapneumovirus infection, pathogenesis, and protective immunity. J Virol 79 17 (2005) 10944-10951
119. Prince G.A., Curtis S.J., Yim K.C., et al. Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine. J Gen Virol 82 Pt 12 (2001) 2881-2888
120. Niewiesk S., and Prince G. Diversifying animal models: the use of cotton rats (Sigmodon hispidus) in infectious diseases. Lab Anim 36 (2002) 357-372
121. Biacchesi S., Skiadopoulos M.H., Tran K.C., et al. Recovery of human metapneumovirus from cDNA: optimization of growth in vitro and expression of additional genes. Virology 321 2 (2004) 247-259
122. Biacchesi S., Pham Q.N., Skiadopoulos M.H., et al. Infection of nonhuman primates with recombinant human metapneumovirus lacking the SH, G, or M2-2 protein categorizes each as a nonessential accessory protein and identifies vaccine candidates. J Virol 79 19 (2005) 12608-12613
123. Pham Q.N., Biacchesi S., Skiadopoulos M.H., et al. Chimeric recombinant human metapneumoviruses with the nucleoprotein or phosphoprotein open reading frame replaced by that of avian metapneumovirus exhibit improved growth in vitro and attenuation in vivo. J Virol 79 24 (2005) 15114-15122
124. Ksiazek T.G., Erdman D., Goldsmith C.S., et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 348 20 (2003) 1953-1966
125. Rota P.A., Oberste M.S., Monroe S.S., et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300 5624 (2003) 1394-1399
126. Drosten C., Gunther S., Preiser W., et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 348 20 (2003) 1967-1976
127. Fouchier R.A., Kuiken T., Schutten M., et al. Aetiology: Koch's postulates fulfilled for SARS virus. Nature 423 6937 (2003) 240
128. Fouchier R.A., Hartwig N.G., Bestebroer T.M., et al. A previously undescribed coronavirus associated with respiratory disease in humans. Proc Natl Acad Sci U S A 101 16 (2004) 6212-6216
129. van der Hoek L., Pyrc K., Jebbink M.F., et al. Identification of a new human coronavirus. Nat Med 10 4 (2004) 368-373
130. van der Hoek L., Sure K., Ihorst G., et al. Croup is associated with the novel coronavirus NL63. PLoS Med 2 8 (2005) e240
131. Hofmann H., Pyrc K., van der Hoek L., et al. Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. Proc Natl Acad Sci U S A 102 22 (2005) 7988-7993
132. Pyrc K., Bosch B.J., Berkhout B., et al. Inhibition of human coronavirus NL63 infection at early stages of the replication cycle. Antimicrob Agents Chemother 50 6 (2006) 2000-2008
133. Reynolds E.O., and Cook C.D. The Treatment Of Bronchiolitis. J Pediatr 63 (1963) 1205-1207
134. Sigurs N., Bjarnason R., Sigurbergsson F., et al. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med 161 5 (2000) 1501-1507
135. Sigurs N., Gustafsson P.M., Bjarnason R., et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med 171 2 (2005) 137-141
136. Lemanske Jr. R.F. Viruses and asthma: inception, exacerbation, and possible prevention. J Pediatr 142 2 Suppl (2003) S3-S7 [discussion S7-8]
137. Gern J.E., and Lemanske Jr. R.F. Infectious triggers of pediatric asthma. Pediatr Clin North Am 50 3 (2003) 555-575
138. Moore M.L., and Peebles Jr. R.S. Respiratory syncytial virus disease mechanisms implicated by human, animal model, and in vitro data facilitate vaccine strategies and new therapeutics. Pharmacol Ther (2006) epub ahead of print
139. Martinez F.D. Respiratory syncytial virus bronchiolitis and the pathogenesis of childhood asthma. Pediatr Infect Dis J 22 2 Suppl (2003) S76-S82
140. Patel H., Platt R., Lozano J.M., et al. Glucocorticoids for acute viral bronchiolitis in infants and young children. Cochrane Database Syst Rev 3 (2004) CD004878
141. Hartling L., Wiebe N., Russell K., et al. Epinephrine for bronchiolitis. Cochrane Database Syst Rev 1 (2004) CD003123
142. Gadomski A., and Bhasale A. Bronchodilators for bronchiolitis. Cochrane Database Syst Rev 3 (2006) CD001266
143. Soto M.E., Sly P.D., Uren E., et al. Bronchodilator response during acute viral bronchiolitis in infancy. Pediatr Pulmonol 1 2 (1985) 85-90
144. Kim C.K., Koh J.Y., Han T.H., et al. Increased levels of BAL cysteinyl leukotrienes in acute RSV bronchiolitis. Acta Paediatr 95 4 (2006) 479-485
145. Piedimonte G., Renzetti G., Auais A., et al. Leukotriene synthesis during respiratory syncytial virus bronchiolitis: influence of age and atopy. Pediatr Pulmonol 40 4 (2005) 285-291
146. Bisgaard H., and Study Group on Montelukast and Respiratory Syncytial Virus. A randomized trial of montelukast in respiratory syncytial virus postbronchiolitis. Am J Respir Crit Care Med 167 3 (2003) 379-383
147. Szefler S.J., and Simoes E.A. Montelukast for respiratory syncytial virus bronchiolitis: significant effect or provocative findings?. Am J Respir Crit Care Med 167 3 (2003) 290-291
148. Nasr S.Z., Strouse P.J., Soskolne E., et al. Efficacy of recombinant human deoxyribonuclease I in the hospital management of respiratory syncytial virus bronchiolitis. Chest 120 1 (2001) 203-208
149. Merkus P.J., de Hoog M., van Gent R., et al. DNase treatment for atelectasis in infants with severe respiratory syncytial virus bronchiolitis. Eur Respir J 18 4 (2001) 734-737
150. Kerr M.H., and Paton J.Y. Surfactant protein levels in severe respiratory syncytial virus infection. Am J Respir Crit Care Med 159 4 Pt 1 (1999) 1115-1118
151. LeVine A.M., Gwozdz J., Stark J., et al. Surfactant protein-A enhances respiratory syncytial virus clearance in vivo. J Clin Invest 103 7 (1999) 1015-1021
152. LeVine A.M., Elliott J., Whitsett J.A., et al. Surfactant protein-d enhances phagocytosis and pulmonary clearance of respiratory syncytial virus. Am J Respir Cell Mol Biol 31 2 (2004) 193-199
153. Tibby S.M., Hatherill M., Wright S.M., et al. Exogenous surfactant supplementation in infants with respiratory syncytial virus bronchiolitis. Am J Respir Crit Care Med 162 4 Pt 1 (2000) 1251-1256
154. Ventre K., Haroon M., and Davison C. Surfactant therapy for bronchiolitis in critically ill infants. Cochrane Database Syst Rev 3 (2006) CD005150
155. Henrickson K.J. Advances in the laboratory diagnosis of viral respiratory disease. Pediatr Infect Dis J 23 1 Suppl (2004) S6-S10
156. Henrickson K.J. Cost-effective use of rapid diagnostic techniques in the treatment and prevention of viral respiratory infections. Pediatr Ann 34 1 (2005) 24-31
157. Puppe W., Weigl J.A., Aron G., et al. Evaluation of a multiplex reverse transcriptase PCR ELISA for the detection of nine respiratory tract pathogens. J Clin Virol 30 2 (2004) 165-174
158. Briese T., Palacios G., Kokoris M., et al. Diagnostic system for rapid and sensitive differential detection of pathogens. Emerg Infect Dis 11 2 (2005) 310-313
159. Kehl S.C., Henrickson K.J., Hua W., et al. Evaluation of the Hexaplex assay for detection of respiratory viruses in children. J Clin Microbiol 39 5 (2001) 1696-1701
160. Fan J., Henrickson K.J., and Savatski L.L. Rapid simultaneous diagnosis of infections with respiratory syncytial viruses A and B, influenza viruses A and B, and human parainfluenza virus types 1, 2, and 3 by multiplex quantitative reverse transcription-polymerase chain reaction-enzyme hybridization assay (Hexaplex). Clin Infect Dis 26 6 (1998) 1397-1402
161. Fan J., and Henrickson K.J. Rapid diagnosis of human parainfluenza virus type 1 infection by quantitative reverse transcription-PCR-enzyme hybridization assay. J Clin Microbiol 34 8 (1996) 1914-1917
162. Kuypers J., Wright N., Corey L., et al. Detection and quantification of human metapneumovirus in pediatric specimens by real-time RT-PCR. J Clin Virol 33 4 (2005) 299-305
163. Maertzdorf J., Wang C.K., Brown J.B., et al. Real-time reverse transcriptase PCR assay for detection of human metapneumoviruses from all known genetic lineages. J Clin Microbiol 42 3 (2004) 981-986
164. Mackay I.M., Jacob K.C., Woolhouse D., et al. Molecular assays for detection of human metapneumovirus. J Clin Microbiol 41 1 (2003) 100-105
165. Cote S., Abed Y., and Boivin G. Comparative evaluation of real-time PCR assays for detection of the human metapneumovirus. J Clin Microbiol 41 8 (2003) 3631-3635
166. Moes E., Vijgen L., Keyaerts E., et al. A novel pancoronavirus RT-PCR assay: frequent detection of human coronavirus NL63 in children hospitalized with respiratory tract infections in Belgium. BMC Infect Dis 5 1 (2005) 6
167. Stephensen C.B., Casebolt D.B., and Gangopadhyay N.N. Phylogenetic analysis of a highly conserved region of the polymerase gene from 11 coronaviruses and development of a consensus polymerase chain reaction assay. Virus Res 60 2 (1999) 181-189